Welcome to the SYMDEKOhcp.com e-mail registration page

SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

If you would like to receive e-mails regarding updates to this website, as well as information about Vertex and/or its cystic fibrosis medicines, please sign up below.

Please note that by submitting your information below, you certify that you are a physician, nurse, or other healthcare professional involved in the care of patients and that you reside and practice in the United States.